Special Issue "Long-Term Effects of Systemic Therapies on Cancer Patients"

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Dr. Andrew G. Robinson
E-Mail Website
Guest Editor
Departments of Oncology, Queen's University, Kingston, ON K7L 5P9, Canada
Interests: breast cancer; lung cancer; translational research; predictive and prognostic biomarkers; cancer treatment

Special Issue Information

Dear Colleagues,

Chemotherapy and hormonal therapy have been the cornerstone of systemic therapy for cancer patients for the past 70 years, while, more recently, targeted therapy, monoclonal antibody therapy, and immunotherapy have seen significant increases in use. Given the increasing incidence of cancer, the changing age demographics of the affected population, the increased indications for therapies in earlier stages of disease, and the increased efficacy of recent therapies, there is a growing number of long-term survivors who have been treated with systemic chemotherapy, immunotherapy, hormonal therapy, and targeted therapy. This Special Issue focuses on the long-term effects of these therapies that require special attention in cancer survivors.

Dr. Andrew G. Robinson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • late effects
  • survivorship
  • toxicity
  • immunotherapy
  • targeted therapy
  • chemotherapy hormonal therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Case Report
An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)
Curr. Oncol. 2021, 28(3), 1980-1987; https://doi.org/10.3390/curroncol28030184 - 25 May 2021
Viewed by 645
Abstract
Background. Personalized therapy is becoming increasingly popular in oncological scenarios, not only based on molecular pharmacological targets, but also preventing any drug–drug–gene interaction (DDGI), which could lead to severe toxicities. Single nucleotide polymorphisms (SNPs), the individual germline sequence variations in genes involved in [...] Read more.
Background. Personalized therapy is becoming increasingly popular in oncological scenarios, not only based on molecular pharmacological targets, but also preventing any drug–drug–gene interaction (DDGI), which could lead to severe toxicities. Single nucleotide polymorphisms (SNPs), the individual germline sequence variations in genes involved in drug metabolism, are correlated to interindividual response to drugs and explain both efficacy and toxicity profiles reported by patients. Case presentation. We present the case of a woman suffering from triple-positive breast cancer; she had early-stage disease at the onset and after four years developed metastatic disease. During her history, she presented different toxicities due to antineoplastic treatments. Particularly, hypertransaminasemia was found during every line of treatment. Nevertheless, we were able to guarantee the patient an excellent therapeutic adhesion thanks to the supportive treatments and the reduction of drug dosage. Moreover, we conducted a simultaneous analysis of the patient’s biochemical and genomic data thanks to Drug-PIN software, and we found several significant SNPs of the main enzymes and transporters involved in drug metabolism. Conclusion. Our case report demonstrated the relevance of DDGI in clinical practice management of a patient treated for advanced breast cancer, suggesting the role of Drug-PIN software as an easy-to-use tool to prevent adverse events during cancer treatment and to help physicians in therapeutic algorithms. However, further studies are needed to confirm these results. Full article
(This article belongs to the Special Issue Long-Term Effects of Systemic Therapies on Cancer Patients)
Show Figures

Figure 1

Back to TopTop